Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CFRXNASDAQ:GRTXNASDAQ:SHPHNASDAQ:SILO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCFRXContraFect$0.05$0.05$0.04▼$13.02$535K0.291.39 million shs910,216 shsGRTXGalera Therapeutics$0.02$0.03$0.02▼$0.23$1.77M1.77104,908 shs136,484 shsSHPHShuttle Pharmaceuticals$0.17-4.3%$0.29$0.16▼$4.71$1.89M-0.931.59 million shs992,877 shsSILOSilo Pharma$0.45-4.7%$0.90$0.41▼$4.50$2.02M0.372.22 million shs165,323 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCFRXContraFect0.00%0.00%0.00%0.00%0.00%GRTXGalera Therapeutics-3.69%+0.86%+2.17%-38.64%-88.01%SHPHShuttle Pharmaceuticals+6.47%+1.17%-38.23%-70.27%+18,099,900.00%SILOSilo Pharma+2.88%+10.40%-41.70%-65.15%-75.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCFRXContraFectN/AN/AN/AN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASHPHShuttle Pharmaceuticals0.4742 of 5 stars0.02.00.00.02.50.80.6SILOSilo Pharma0.4348 of 5 stars0.01.00.00.02.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCFRXContraFect 0.00N/AN/AN/AGRTXGalera Therapeutics 0.00N/AN/AN/ASHPHShuttle Pharmaceuticals 0.00N/AN/AN/ASILOSilo Pharma 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCFRXContraFectN/AN/AN/AN/A($19.92) per shareN/AGRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/A$2.03 per shareN/ASILOSilo Pharma$72.10K27.99N/AN/A$2.14 per share0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCFRXContraFect-$65.15M-$19.27N/AN/AN/AN/AN/A-138.70%N/AGRTXGalera Therapeutics-$59.08M-$0.35N/A∞N/AN/AN/A-99.34%8/12/2025 (Estimated)SHPHShuttle Pharmaceuticals-$6.59M-$4.15N/A∞N/AN/A-583.02%-258.92%N/ASILOSilo Pharma-$3.70M-$1.17N/A∞N/A-5,255.05%-61.38%-47.49%8/11/2025 (Estimated)Latest CFRX, SILO, SHPH, and GRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025SILOSilo PharmaN/A-$0.23N/A-$0.23N/A$0.02 million5/8/2025Q1 2025SHPHShuttle PharmaceuticalsN/A-$0.30N/A-$0.30N/AN/A3/28/2025Q4 2024SILOSilo PharmaN/A-$0.41N/A-$0.41N/A$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCFRXContraFectN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/AN/ASILOSilo PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCFRXContraFectN/A0.530.53GRTXGalera TherapeuticsN/A9.749.74SHPHShuttle PharmaceuticalsN/A0.220.22SILOSilo PharmaN/A7.917.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCFRXContraFect7.85%GRTXGalera Therapeutics50.77%SHPHShuttle Pharmaceuticals4.58%SILOSilo Pharma5.58%Insider OwnershipCompanyInsider OwnershipCFRXContraFect0.62%GRTXGalera Therapeutics12.90%SHPHShuttle Pharmaceuticals12.60%SILOSilo Pharma4.37%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCFRXContraFect2310.70 million10.64 millionNot OptionableGRTXGalera Therapeutics3075.46 million47.38 millionOptionableSHPHShuttle Pharmaceuticals510.98 million2.46 millionNot OptionableSILOSilo Pharma24.48 million4.29 millionNot OptionableCFRX, SILO, SHPH, and GRTX HeadlinesRecent News About These CompaniesSilo Pharma, Inc.: Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15May 23, 2025 | finanznachrichten.deSilo Pharma teams up with Resyca for IND-supporting intranasal drug-device study of PTSD drugMay 21, 2025 | msn.comSilo Pharma, Inc. Partners with Resyca BV for SPC-15 Drug-Device Study Aimed at PTSD TreatmentMay 21, 2025 | quiverquant.comSilo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15May 21, 2025 | globenewswire.comSilo Pharma, Inc.: Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15May 16, 2025 | finanznachrichten.deSilo Pharma Signs With Frontage Labs For FDA Requested Safety Study Of SPC-15May 16, 2025 | nasdaq.comSilo Pharma Announces Closing of $2 Million Public OfferingMay 16, 2025 | globenewswire.comSilo Pharma Retail Buzz Surges On FDA Toxicology Study Plans For PTSD TreatmentMay 16, 2025 | msn.comSilo Pharma, Inc. Prices Public Offering of 3,333,338 Shares with Associated WarrantsMay 15, 2025 | quiverquant.comSilo Pharma Announces Pricing of $2 Million Public OfferingMay 15, 2025 | globenewswire.comSilo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15May 14, 2025 | globenewswire.comSilo Pharma, Inc. Announces Agreement with Frontage Laboratories for SPC-15 Safety and Toxicology Study Targeting PTSD TreatmentMay 14, 2025 | quiverquant.comSilo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage LaboratoriesMay 14, 2025 | globenewswire.comCounterproposal to Swiss cost-cutting initiativeMay 12, 2025 | thepharmaletter.comSilo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia StudyApril 30, 2025 | finance.yahoo.comSilo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia StudyApril 30, 2025 | globenewswire.comSilo Pharma Files Patent Application for Alzheimer's Drug SPC-14 Targeting Novel Mechanism of ActionApril 29, 2025 | nasdaq.comSarasota company applies for Alzheimer's drug patentApril 29, 2025 | businessobserverfl.comSilo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s DrugApril 28, 2025 | finance.yahoo.comSilo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's DrugApril 28, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCFRX, SILO, SHPH, and GRTX Company DescriptionsContraFect NASDAQ:CFRXContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.Galera Therapeutics NASDAQ:GRTX$0.02 0.00 (0.00%) As of 03:48 PM EasternGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Shuttle Pharmaceuticals NASDAQ:SHPH$0.17 -0.01 (-4.33%) Closing price 04:00 PM EasternExtended Trading$0.17 0.00 (-1.28%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.Silo Pharma NASDAQ:SILO$0.45 -0.02 (-4.70%) Closing price 04:00 PM EasternExtended Trading$0.46 +0.01 (+2.00%) As of 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
